4,784 Shares in Vericel Corporation $VCEL Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC bought a new position in Vericel Corporation (NASDAQ:VCEL) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,784 shares of the biotechnology company’s stock, valued at approximately $204,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in VCEL. Ameritas Advisory Services LLC purchased a new stake in Vericel during the second quarter valued at approximately $30,000. GAMMA Investing LLC raised its position in Vericel by 34.8% during the first quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 748 shares during the period. Gagnon Securities LLC purchased a new stake in Vericel during the first quarter valued at approximately $137,000. US Bancorp DE raised its position in Vericel by 29.9% during the first quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 706 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Vericel in the first quarter worth approximately $242,000.

Vericel Stock Performance

Shares of VCEL opened at $36.32 on Friday. The stock has a 50-day moving average of $33.68 and a two-hundred day moving average of $38.10. Vericel Corporation has a one year low of $29.24 and a one year high of $63.00. The stock has a market cap of $1.83 billion, a P/E ratio of 302.69 and a beta of 1.39.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company had revenue of $63.24 million during the quarter, compared to analysts’ expectations of $64.61 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. The firm’s revenue was up 20.1% compared to the same quarter last year. Analysts predict that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Analyst Ratings Changes

VCEL has been the topic of several recent analyst reports. Canaccord Genuity Group reduced their price target on Vericel from $61.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Vericel in a research note on Friday. Truist Financial dropped their price objective on Vericel from $46.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. BTIG Research cut Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Finally, Zacks Research raised Vericel from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $58.40.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.